Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results
October 29, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a...
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
October 19, 2020 14:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 09, 2020 15:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update
August 05, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20Constellation plans to explore additional indications for...
Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
July 31, 2020 12:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
June 16, 2020 20:27 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 15, 2020 16:01 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
June 12, 2020 02:30 ET
|
Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
Constellation Pharmaceuticals to Participate in Investor Conference
June 10, 2020 11:30 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Appointment of Dr. Jeffrey Humphrey as Chief Medical Officer
June 08, 2020 08:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...